

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:52:56 ON 18 NOV 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2002 HIGHEST RN 473758-49-5
 DICTIONARY FILE UPDATES: 15 NOV 2002 HIGHEST RN 473758-49-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s sercin
 L1 0 SERCIN

=> s sericin/cn
 L2 0 SERICIN/CN

=> s sericin
 L3 5 SERICIN

=> d l3

L3 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS
 RN 193488-76-5 REGISTRY
 CN Sericin 1 (silkworm gene Ser1 isoform Ser1B precursor reduced)
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank Z48802-derived protein GI 755700
 FS PROTEIN SEQUENCE
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d l3 1-5

L3 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS
 RN 193488-76-5 REGISTRY
 CN Sericin 1 (silkworm gene Ser1 isoform Ser1B precursor reduced)
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank Z48802-derived protein GI 755700
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 164246-47-3 REGISTRY
CN DNA (silkworm gene Ser1 sericin 1 isoform Ser1B cDNA plus flanks)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank Z48802
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: AGRICOLA, CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 60650-89-7 REGISTRY
CN Sericin B (9CI) (CA INDEX NAME)
MF Unspecified
CI PMS, MAN
PCT Manual registration
LC STN Files: BIOBUSINESS, BIOSIS, CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 60650-88-6 REGISTRY
CN Sericin A (9CI) (CA INDEX NAME)
MF Unspecified
CI PMS, MAN
PCT Manual registration
LC STN Files: AGRICOLA, CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 37332-47-1 REGISTRY
CN Sericinase (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
LC STN Files: BIOSIS, CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
22.24	22.45

FULL ESTIMATED COST

FILE 'ADISALERTS' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'BIOSIS' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 09:53:54 ON 18 NOV 2002

FILE 'CAPLUS' ENTERED AT 09:53:54 ON 18 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IPA' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (c) 2002 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 09:53:54 ON 18 NOV 2002

FILE 'NAPRALERT' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'PASCAL' ENTERED AT 09:53:54 ON 18 NOV 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PHARMAML' ENTERED AT 09:53:54 ON 18 NOV 2002
Copyright 2002 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TOXCENTER' ENTERED AT 09:53:54 ON 18 NOV 2002
COPYRIGHT (C) 2002 ACS

FILE 'USPATFULL' ENTERED AT 09:53:54 ON 18 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:53:54 ON 18 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 09:52:35 ON 18 NOV 2002)

FILE 'REGISTRY' ENTERED AT 09:52:56 ON 18 NOV 2002

L1 0 S SERCIN
L2 0 S SERICIN/CN
L3 5 S SERICIN

FILE 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, PASCAL, ...' ENTERED AT 09:53:54 ON 18 NOV 2002

=> s l3 or sericin
18 FILES SEARCHED...

L4 2114 L3 OR SERICIN

=> s cancer
9 FILES SEARCHED...
27 FILES SEARCHED...

L5 .5113519 CANCER

=> s l4 and l5
L6 19 L4 AND L5

=> s skin (p) cancer
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
17 FILES SEARCHED...

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'SKIN (P) CANCER'
32 FILES SEARCHED...

L7 167056 SKIN (P) CANCER

=> s l6 and l7
10 FILES SEARCHED...
28 FILES SEARCHED...

L8 7 L6 AND L7

=> dup rem
ENTER L# LIST OR (END):18
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH, DRUGMONOG2, KOSMET, MEDICONF, PHARMAML'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L8

L9 4 DUP REM L8 (3 DUPLICATES REMOVED)

=> d l9 1-4 bib, ab, kwic

L9 ANSWER 1 OF 4 USPATFULL
AN 2002:230632 USPATFULL
TI Anti-inflammatory analgesic
IN Niiyiro, Yasunori, Fujinomiya, JAPAN
Koda, Shigeru, Shizuoka, JAPAN
Sugiyama, Satoru, Nagoya, JAPAN
PA Nippon Hypox Laboratories Inc., Tokyo, JAPAN (non-U.S. corporation)
PI US 6447817 B1 20020910
WO 2000009121 20000224
AI US 2001-744299 20010123 (9)
WO 1999-JP4308 19990810
20010123 PCT 371 date
PRAI JP 1998-259088 19980810

DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Lankford, Jr., Leon B.; Assistant Examiner: Davis, Ruth A.
 LREP Nixon & Vanderhye P.C.
 CLMN Number of Claims: 2
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 453
 AB The present invention is concerned with an anti-inflammation analgesic preparation which contains a specific 3-0-substituted ascorbic acid as an active ingredient, shows excellent anti-inflammation analgesic effects and is excellent in shelf life, safety to a skin and endermic absorptivity of the active ingredient.
 SUMM . . . invention is a known ascorbic acid derivative which generally has anti-oxidative activity and is recognized to have carcinogenesis inhibition activity, **cancer**-metastasis prevention activity, fair **skin** making activity. Further, WO91/03471 refers to an organ-disorder inhibition activity based on inhibition activity against a lipid peroxidation.
 SUMM . . . squalane oil, beef tallow, lard, Japan wax, beeswax, candelilla wax, carnauba wax, spermaceti, lanolin, silicone oil, fluorine oil, liquid paraffin, **sericin**, petrolatum, polyoxyethyleneoleyl alcohol ether, glycerin ethylhexanoate, pentaerythritol ethylhexanoate, cetyl ethylhexanoate, glyceryl monooleate, etc., higher alcohols such as capryl alcohol, lauryl. . .

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
 AN 2001:924315 CAPLUS
 DN 136:31673
 TI **Sericin skin cancer** preventive agent
 IN Jin, Zongxuan; Muramatsu, Koichiro; Yamada, Hideyuki; Fuwa, Naozumi; Hibasami, Hiroshige
 PA Kabushiki Kaisha Aioi Hakko, Japan; Seiren Kabushiki Kaisha
 SO U.S. Pat. Appl. Publ., 4 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001053759	A1	20011220	US 2001-863316	20010524
	JP 2001354584	A2	20011225	JP 2000-178776	20000614
	EP 1166795	A2	20020102	EP 2001-113730	20010605
	EP 1166795	A3	20020227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI JP 2000-178776 A 20000614

AB The present invention provides a **skin cancer** preventive agent that inhibits the promotion of carcinogenesis of **skin cancer** while having high levels of safety and stability as well as being free of adverse side effects. The present invention is characterized by contg. **sericin**.

TI **Sericin skin cancer** preventive agent

AB The present invention provides a **skin cancer** preventive agent that inhibits the promotion of carcinogenesis of **skin cancer** while having high levels of safety and stability as well as being free of adverse side effects. The present invention is characterized by contg. **sericin**.

ST **sericin skin cancer** prevention

IT **Skin**, neoplasm
 (carcinoma, inhibitors; **sericin skin cancer** preventive agent)

IT **Skin**, neoplasm

(inhibitors; **sericin** skin cancer preventive agent)

IT Sericins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**sericin** skin cancer preventive agent)

IT Antitumor agents
 (**skin** carcinoma; **sericin** skin cancer preventive agent)

IT Antitumor agents
 (**skin**; **sericin** skin cancer preventive agent)

L9 ANSWER 3 OF 4 USPATFULL
 AN 2001:32816 USPATFULL
 TI Composition for external use
 IN Abe, Koji, Kanagawa, Japan
 Miyahara, Reiji, Kanagawa, Japan
 Nanba, Tomiyuki, Kanagawa, Japan
 Nakamura, Tadashi, Kanagawa, Japan
 Hayashi, Toshikatsu, Kanagawa, Japan
 Seki, Nozomiko, Kanagawa, Japan
 Uehara, Keiichi, Osaka, Japan
 Nishiyama, Syoji, Kanagawa, Japan
 PA Shiseido Company, Ltd., Tokyo, Japan (non-U.S. corporation)
 PI US 6197318 B1 20010306
 WO 9926590 19990603
 AI US 1999-341146 19990716 (9)
 WO 1998-JP4040 19980909
 19990716 PCT 371 date
 19990716 PCT 102(e) date

PRAI JP 1997-337916 19971120
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Dodson, Shelley A.
 LREP Townsend & Banta
 CLMN Number of Claims: 27
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2291
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for external use which contains xyloglucan. It preferably further contains an ultraviolet shielding agent, a thickening polysaccharide, a thickening polysaccharide and **sericin**, a carboxyvinylpolymer, or an alkyl-modified carboxyvinylpolymer.

AB . . . external use which contains xyloglucan. It preferably further contains an ultraviolet shielding agent, a thickening polysaccharide, a thickening polysaccharide and **sericin**, a carboxyvinylpolymer, or an alkyl-modified carboxyvinylpolymer.

SUMM For example, an ultraviolet shielding agent is incorporated into an external-use composition in order to protect the **skin** from exposure to ultraviolet rays in sunlight, so as to prevent generation of age spots or freckles and **skin** aging, as well as to prevent generation of **skin** diseases such as **skin cancer**. When an external-use composition is processed into an emulsion such as milky lotion or cream or is stabilized, a surfactant.

SUMM C. A third mode of the present invention is directed to an external-use composition in which xyloglucan, thickening polysaccharides, and **sericin** are incorporated (hereinafter the composition will be referred to as the "external-use composition of the third mode of the present. . .

SUMM The present inventors found that the aforementioned external-use composition containing xyloglucan, thickening polysaccharides, and

sericin has not only good moisturizing effect on the skin but also favorable sensation in use, such as good fit for. . .

SUMM **Sericin** which may be incorporated into the composition is a hydrophilic protein contained in silk threads which are produced by a . . .

SUMM In the external-use composition of the third mode of the present invention, the amount of incorporated **sericin** is 0.001-5.0 wt. %, preferably 0.01-3.0 wt. %, with respect to the entirety of the composition.

SUMM In the external-use composition of the third mode of the present invention, when **sericin** is incorporated in an amount of less than 0.001 wt. % with respect to the entirety of the composition, substantial. . . no stickiness. When the amount thereof is more than 5.0 wt. % with respect to the entirety of the composition, **sericin** forms a film on the skin and provides a sticky sensation.

SUMM In addition to the aforementioned ingredients (xyloglucan, thickening polysaccharides, **sericin**), other ingredients which are usually utilized for external-use compositions may be appropriately incorporated into the external-use composition of the third. . .

SUMMgamma.-oryzanol, allantoin, glycyrrhizic acid (salts), glycyrrhetic acid and derivatives thereof, extracts from a variety of animals and plants (other than **sericin**), hinokitiol, bisabolol, eucalyptus, thymol, inositol, saponins, pantothenyl ethyl ether, ethynylestradiol, tranexamic acid, arbutin, cepharanthine, and placenta extract.

DETD

(5) hydroxyethylcellulose	-- -- -- 2.0	-- --
(6) xanthan gum	-- -- -- 2.0	--
(7) sericin	-- -- -- 2.0	
(8) preservative	s.a. s.a. s.a. s.a. s.a. s.a.	
(9) perfume	s.a. s.a. s.a. s.a.. . .	

DETD

(4) hydroxyethylcellulose	1.0 1.0 0.1 2.0	-- 0.1
(5) xanthan gum	1.0 1.0 -- -- 0.1	0.1
(6) sericin	1.0 0.1 1.0 1.0	1.0 1.0
(7) preservative	s.a. s.a. s.a. s.a. s.a. s.a.	
(8) perfume	s.a. s.a. s.a. s.a. s.a. s.a.	
(9) . . .		

DETD As shown in Table C3 and Table C4, incorporation of xyloglucan, a thickening polysaccharide, and **sericin** has a synergistic effect, thus yielding an external-use composition having superior moisture retention and advantageous sensation in use.

DETD . . . propyleneglycol monostearate

1.5

(9) POE (20) cetyl alcohol ether	1.5
(10) triethanolamine	1.0
(11) xyloglucan	1.0
(12) hydroxyethylcellulose	1.0
(13) sericin	0.5
(14) preservative	suitable amount
(15) antioxidant	suitable amount
(16) perfume	suitable amount
(17) purified water	balance

DETD . . . 4.0

(9) POE (10) monooleic acid ester	1.0
(10) glyceryl monostearate	1.0
(11) xyloglucan	2.0
(12) xanthan gum	0.1
(13) sericin	1.0
(14) preservative	suitable amount
(15) colorant	suitable amount
(16) perfume	suitable amount
(17) purified water	balance

DETD 0.1

- (6) polyoxyethylene sorbitan monostearate 0.9
- (7) triethanolamine 1.0
- (8) propylene glycol 5.0
- (9) hydroxyethylcellulose 0.5
- (10) xyloglucan 0.5
- (11) **sericin** 0.5
- (12) stearic acid 2.2
- (13) isohexadecyl alcohol 7.0
- (14) glyceryl monostearate 2.0
- (15) liquid lanolin 2.0
- (16) liquid paraffin. . .

CLM What is claimed is:

11. The external-use composition according to claim 6, further comprising **sericin**.

12. The external-use composition according to claim 11, wherein amounts of the xyloglucan, the thickening polysaccharide, and the **sericin** are as follows: (A) xyloglucan: 0.01-5.0% by weight with respect to the entirety of the external-use composition; (B) thickening polysaccharide: 0.01-5.0% by weight with respect to the entirety of the external-use composition; and (A) **sericin**: 0.001-5.0% by weight with respect to the entirety of the external-use composition.

L9 ANSWER 4 OF 4 USPATFULL

AN 86:57906 USPATFULL

TI Process for producing immobilized L-asparaginase preparations for the therapy of leukemia

IN Nambu, Masao, Yokohama, Japan

PA Nippon Oil Company, Limited, Tokyo, Japan (non-U.S. corporation)

PI US 4617271 19861014

WO 8303763 19831110

AI US 1983-573922 19831216 (6)

WO 1983-JP126 19830421

19831216 PCT 371 date

19831216 PCT 102(e) date

PRAI JP 1982-65466 19820421

DT Utility

FS Granted

EXNAM Primary Examiner: Marantz, Sidney; Assistant Examiner: Krawczewicz, L.

LREP Scully, Scott, Murphy & Presser

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1070

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a process for producing immobilized L-asparaginase preparations. Its principal object is to produce immobilized L-asparaginase preparations which are excellent in antithrombogenicity and mechanical strength.

The present invention is concerned with production of immobilized L-asparaginase preparations by pouring an aqueous solution containing 6% or more of a polyvinyl alcohol with a degree of hydrolysis of 97 mol. % or higher and a viscosity-average degree of polymerization of 1,800 or more an antileukemic asparaginase into a vessel or a mold of an appropriate shape, subjecting the solution to cooling, solidification and molding at a temperature of -15.degree. C. or lower and partially dehydrating the molded mass without thawing to a dehydration ratio of 5% by weight or more and, if desired, immersing the product in water.

According to the invention, L-asparaginase can be embedded in a highly hydrous gel excellent in antithrombogenicity and mechanical strength by

simple procedures.

SUMM . . . 18, 1380 (1968)). Clinical trials were extensively carried out using asparaginase from Escherichia coli B (R. H. Adamson et al., **Cancer Chemother. Rep.**, (1) 52, 617 (1968)). It was pointed out as a result of the trials that antigen-antibody reaction (immunoreaction). . . body was a problem; side effects such as vomiting, nausea, anorexia, pyrexia, bodyweight decrease, hypohepatia, pancreatitis, oligochromemia, uremia, fibrinogenopenia, hyponoia, **skin** rash, diarrhea, pararitium, anemia, leukopenia, thrombocytopenia, anaphylaxic shock, cephalalgia, angiodynia, irritation and cramp were observed (P. Laboureur, Pathol. Biol. (Paris),

DETD . . . 0.1 mm in diameter, sterilized at 120.degree. C. for 30 min.) which had been subjected to a dissolution treatment with **sericin**, a catgut (intestine wire, 0.18 mm in diameter. Sterilized with ethylene oxide), a Dexon thread (polyglycolic acid, 0.18 mm in. . . .

DETD . . . a high dose (L. T. Mashburn et al., Biochem. Biophys. Res. Commun., 12, 50 (1963), R. H. Adamson et al., **Cancer Chemther. Rep.**, (1)52, 617 (1968)), which often produce severe side-effects. On the contrary, durable effects of the immobilized enzyme preparation. .

=>